Latest news with #HEALWELL
Globe and Mail
16-07-2025
- Business
- Globe and Mail
HEALWELL Provides Corporate Update Including Improved Performance in AI Business, Acquisition of Remaining Interest in Pentavere and Deeper Integration within the AI Business Segment
HEALWELL announced improved performance for its core AI business segment with preliminary revenues expected to exceed $5 million for the first six months of 2025, reflecting a year-over-year increase of over 200% as compared to the same period last year. This strong performance is expected to lead to positive Adjusted EBITDA for the AI business segment during the first six months of the year. HEALWELL acquires remaining 49% of Pentavere Research Group Inc., by exercising a call option to gain full ownership of the business. Pentavere is an award winning and globally renowned AI healthcare company which is responsible for the development of a leading AI-driven patient identification platform, DARWEN. TM With 100% ownership of Pentavere, HEALWELL intends to deepen integration between its AI businesses and accelerate commercialization of AI products across healthcare offerings. Toronto, Ontario--(Newsfile Corp. - July 16, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) (" HEALWELL" or the " Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to provide a corporate update, including improved performance in its AI business units, the acquisition of the remaining interest in Pentavere Research Group Inc. (" Pentavere") and deeper integration of the entities within its AI business segment. The Company's AI business segment, encompassing Pentavere, Khure Health ("Khure"), and Mutuo Health Solutions ("Mutuo") businesses, is on track to exceed $5 million in revenues for the first six months of 2025, ending June 30, 2025, representing a year-over-year increase of over 200%. This strong performance is expected to lead to positive Adjusted EBITDA for the AI business segment during the same period. Strategic Acquisition and Performance Highlights Full Ownership of Pentavere: HEALWELL has exercised its call option to acquire the remaining 49% of Pentavere, gaining full ownership of the globally recognized AI healthcare company. Pentavere is the developer of DARWEN™, a leading AI-driven patient identification platform crucial for preventative care. Robust Organic Growth: Preliminary results for Q2-2025 show significant organic revenue growth within the AI segment, with both Pentavere and Khure each increasing by more than 100% during the first six months of 2025 compared to the same period last year. This demonstrates the Company's enhanced connectivity with the life sciences marketplace. New Leadership and Forward Strategy James Lee, HEALWELL's new Chief Executive Officer, effective July 1, 2025, commented, "I'm incredibly pleased with the strong performance of our core AI division, and I believe its potential is substantial. With Orion Health now part of our family and 100% ownership of Pentavere, we have a unique opportunity to truly differentiate our offering and accelerate the commercialization of our AI products. We are already seeing strong interest in our various AI products, from some of the largest healthcare systems in the world." HEALWELL's strategy is to deeply integrate its AI and data science products into its software platforms. This approach provides a direct path to market, leveraging existing customer bases and contracts to enable healthcare systems worldwide to adopt AI solutions more readily. Hamed Shahbazi, HEALWELL's Chairman, emphasized the significance of Pentavere, "DARWEN™ is a globally unique and recognized AI solution, validated by some of the largest and most complex healthcare systems. Its focus on ethical and compliant training with permissioned data, alongside clinical validation in over 40 publications, positions it to lead the healthcare sector in deploying AI insights for real-world outcomes. We also continue to be greatly impressed with both the capability and thought leadership of the Pentavere team and are excited to watch them continue their efforts to modernize and AI-enable preventative health." Commitment to Preventative Care Mr. Lee further commented on the urgent need for AI in healthcare, "Global healthcare systems face relentless demands amid budgetary and staffing challenges. AI-based tools like Pentavere's DARWEN™ are breaking new frontiers in patient identification and preventative care, holding the potential to save and protect many lives. Our role is to be an enabler of preventative care, and we must act with urgency. We are committed to delivering on our vision, and along with the Company's President, Dr. Alexander Dobranowski, I look forward to sharing key milestones as we achieve them." Transaction Details of Pentavere Call Option Exercise HEALWELL has acquired the remaining 49% of Pentavere which it did not already own by exercising a call option that it had previously negotiated at the time of its original acquisition of a majority interest in Pentavere in 2023 (the " Call Option"). Pursuant to the Call Option, HEALWELL has acquired all of the remaining issued and outstanding shares of Pentavere for an aggregate purchase price of $13,978,244.70, which was satisfied with the issuance of 10,161,562 Subordinate Voting Shares at a deemed price of $1.3756 per share, equal to the 5-Day VWAP on July 11 th, 2025. James Lee Chief Executive Officer HEALWELL AI Inc. Footnotes: "Adjusted EBITDA" is a non-IFRS financial measure and may not be comparable to other similar measures disclosed by other companies. For more information on the composition of this measure, its purpose and a reconciliation to the nearest IFRS measures, please see " Non-IFRS Financial Measures" in the Company's most recent MD&A dated May 12, 2025, a copy of which is available under the Company's profile on SEDAR+ at About HEALWELL AI HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". To learn more about HEALWELL, please visit Forward-Looking Statements Certain statements in this press release, constitute "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including statements about the Company's strategic plan and expected timelines, milestones and future announcements under the plan; and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements are often, but not always, identified by words or phrases such as "mission", "intends", "to be", "coming", "opportunities", "look forward to", "expected" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms . Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward-looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: HEALWELL's ability to integrate its AI technologies into its other service offerings and platforms; HEALWELL's ability to maintain and leverage its relationships with their commercial partners; the continued adoption of the software, tools and solutions created by HEALWELL and its subsidiaries; that HEALWELL will be successful in identifying, executing and integrating new acquisitions, investments and/or partnerships; the stability of general economic and market conditions; sufficiency of working capital and access to financing; HEALWELL's ability to comply with applicable laws and regulations; HEALWELL's continued compliance with third party intellectual property rights; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; technologies working as intended or at all; trends in customer growth and the adoption of new technologies in the industry; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated March 31, 2025, which is available under HEALWELL's SEDAR+ profile at The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements. This news release contains future-oriented financial information and financial outlook information (collectively, "FOFI") about the expected Q2 2025 revenue and Adjusted EBITDA generated by the Company's AI business, which are subject to the same assumptions, risk factors, limitations, and qualifications as set out in the above paragraphs. The actual financial results of the Company's AI business segment may vary from the amounts set out herein and such variation may be material. HEALWELL and its management believe that the FOFI has been prepared on a reasonable basis, reflecting management's best estimates and judgments. However, because this information is subjective and subject to numerous risks, it should not be relied on as necessarily indicative of future results. Except as required by applicable securities laws, HEALWELL undertakes no obligation to update such FOFI. FOFI contained in this news release was made as of the date hereof and was provided for the purpose of providing further information about HEALWELL's anticipated future business operations and strategic plan for the coming year. Readers are cautioned that the FOFI contained in this news release should not be used for purposes other than for which it is disclosed herein.
Yahoo
11-06-2025
- Business
- Yahoo
HEALWELL AI Leverages Orion Health to Power Entry into US Market
HEALWELL launches in the U.S. market a suite of AI enabled tools to complement Orion Health's established software offerings in the U.S. This will bring together HEALWELLs globally validated AI capabilities with Orion Health's best-in-class health data infrastructure software creating a unique offering for the U.S. market. This U.S. market launch leverages Orion Health's deep U.S. sector experience, existing U.S. footprint and multi-decade track record of delivering health data infrastructure software to customers in eight U.S. states. US digital-health market spend reached $160.4 billion in 2024 and is forecast to grow at a 15.4% CAGR from 2025 to 2033 to reach $695.2 billion by 20331. As the U.S. healthcare sector is the largest globally; HEALWELL views the U.S. market as a key jurisdiction of focus. Toronto, Ontario--(Newsfile Corp. - June 11, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce a strategic expansion into the U.S. healthcare market, aligning the group's direction following its acquisition of Orion Health. This move marks a major milestone in HEALWELL's mission to advance preventative care through AI-driven insights and trusted health data infrastructure. With over two decades of experience in the U.S, Orion Health has built a strong foundation supporting health information exchanges (HIEs), accountable care organizations (ACOs), clinically integrated networks (CINs), payers, and health systems. Its technology powers clinical data exchange across eight states, enabling thousands of clinicians to access health information for millions of patients, every day. This embedded presence will give HEALWELL immediate reach and credibility in one of the world's largest and most complex healthcare environments. To support this strategic expansion, HEALWELL has established dedicated U.S. and Canadian teams, reflecting the distinct regulatory, funding, and market dynamics of each region. "Orion has had a material presence in the USA for over two decades," said Brad Porter, Chief Commercial Officer at HEALWELL. "We now have a unique opportunity to accelerate value for our customers by combining Orion's trusted platform with HEALWELL's next-generation AI capabilities. The robust clinical validation and data lineage features differentiates these tools in the market and ultimately reduces friction with regards to clinical adoption." HEALWELL's U.S. strategy will focus on the delivery of value-based care and population health initiatives through two critical capabilities: health data infrastructure and a suite of AI-enabled tools to be made available as a compelling offering to ACOs, CINs, HIEs, payers and health systems. As regulatory frameworks like TEFCA along with convergence of standards towards FHIR reshape the national data landscape, HEALWELL is introducing a modular, FHIR-native repository to work alongside Orion's robust HL7-based data repository. This approach enables a TEFCA-ready, standards-aligned architecture that supports longitudinal patient records, interoperability, and real-time data sharing, while providing a clear upgrade path for existing HIEs and provider networks. Complementing this foundation is HEALWELL's growing suite of AI tools which will be introduced to the market, including AI-enabled clinical search, AI-enabled clinical summarisation and AI-enabled patient identification and risk stratification. These tools are designed to integrate seamlessly into existing clinical infrastructure, helping care teams surface insights faster, reduce administrative burden, and improve clinical outcomes. "The demand for clinically validated and explainable AI is growing fast," said Dr. Alexander Dobranowski, CEO of HEALWELL. "Our ability to embed these tools into existing systems rather than replace them means we can drive impact quickly, without disrupting workflows." To deepen its U.S. market presence, HEALWELL will also focus on strategic partnerships and M&A. Dr. Dobranowski adds, "As highlighted by our track record, we will be continuing to evaluate U.S. oriented partnerships, acquisition opportunities and organic expansion to ensure capital allocation matches the ambition of HEALWELLs purpose of enabling the adoption of AI driven preventative care." Beyond providers and public health systems, HEALWELL also sees growing demand from the life sciences sector, where real-world evidence (RWE) generation, decentralized clinical trial orchestration, and identifying gaps in patient care are increasingly common. With established life sciences partnerships and a platform built for scalability, HEALWELL is well-positioned to support clinical research, clinical development, and outcomes-based engagement in the U.S. market. HEALWELL's subsidiaries Pentavere and Khure Health have an established track record with U.S. life sciences and health system organizations and are currently commercially active with 7 of the top 10 largest pharmaceutical companies globally. "We're seeing real traction and a path to significant growth," said James Lee, incoming CEO of HEALWELL. "We're making excellent progress on integration and go-to-market plans, and we're seeing significant opportunities to both expand responsibly and rationalize expenses to improve operating margins. We're at the start of the curve in proving how AI can improve patient outcomes and help healthcare systems become more targeted with their resources. It's an exciting time for the industry." HEALWELL's U.S. oriented portfolio of capabilities will include HEALWELL Data as a Service, a FHIR complaint data store and a growing suite of AI-enabled tools that support clinical search, patient clinical summarisation, patient identification and patient risk stratification. These capabilities complement Orion Health's established and scaled U.S. offerings, including Amadeus Digital Care Record, Virtuoso Digital Front Door, and Communicate Direct Secure Messaging, creating an integrated platform that will deliver both infrastructure and intelligence to the frontlines of care. Dr. Alexander DobranowskiChief Executive OfficerHEALWELL AI Inc. 1 About HEALWELL HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTCQX Market under the symbol "HWAIF". To learn more about HEALWELL, please visit Forward-Looking Statements Certain statements in this press release, constitute "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including statements about the potential for HEALWELL and Orion Health to develop new products and services, or to enhance or combine existing ones, and the anticipated impact of such products and services; and the anticipated timing, focus and implementation of Healwell's strategic expansion into the U.S. Market; and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements are often, but not always, identified by words or phrases such as "mission", "opportunity", "introducing", "is engaging", "continue to", "improve" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms . Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward-looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: HEALWELL's ability to integrate Orion Health personnel, products, services, customers and relationships; HEALWELL's and Orion Health's ability to maintain and leverage their relationships with their commercial partners; the continued adoption of the software, tools and solutions created by HEALWELL and its subsidiaries; that HEALWELL will be successful in identifying, executing and integrating new acquisitions, investments and/or partnerships, the stability of general economic and market conditions; sufficiency of working capital and access to financing; HEALWELL's ability to comply with applicable laws and regulations; HEALWELL's continued compliance with third party intellectual property rights; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; technologies working as intended or at all; trends in customer growth and the adoption of new technologies in the industry; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated March 31, 2025, which is available under HEALWELL's SEDAR+ profile at The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements. For more information: Pardeep S. SanghaInvestor Relations, HEALWELL AI 604-572-6392ir@ To view the source version of this press release, please visit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
11-06-2025
- Business
- Yahoo
HEALWELL AI Leverages Orion Health to Power Entry into US Market
HEALWELL launches in the U.S. market a suite of AI enabled tools to complement Orion Health's established software offerings in the U.S. This will bring together HEALWELLs globally validated AI capabilities with Orion Health's best-in-class health data infrastructure software creating a unique offering for the U.S. market. This U.S. market launch leverages Orion Health's deep U.S. sector experience, existing U.S. footprint and multi-decade track record of delivering health data infrastructure software to customers in eight U.S. states. US digital-health market spend reached $160.4 billion in 2024 and is forecast to grow at a 15.4% CAGR from 2025 to 2033 to reach $695.2 billion by 20331. As the U.S. healthcare sector is the largest globally; HEALWELL views the U.S. market as a key jurisdiction of focus. Toronto, Ontario--(Newsfile Corp. - June 11, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce a strategic expansion into the U.S. healthcare market, aligning the group's direction following its acquisition of Orion Health. This move marks a major milestone in HEALWELL's mission to advance preventative care through AI-driven insights and trusted health data infrastructure. With over two decades of experience in the U.S, Orion Health has built a strong foundation supporting health information exchanges (HIEs), accountable care organizations (ACOs), clinically integrated networks (CINs), payers, and health systems. Its technology powers clinical data exchange across eight states, enabling thousands of clinicians to access health information for millions of patients, every day. This embedded presence will give HEALWELL immediate reach and credibility in one of the world's largest and most complex healthcare environments. To support this strategic expansion, HEALWELL has established dedicated U.S. and Canadian teams, reflecting the distinct regulatory, funding, and market dynamics of each region. "Orion has had a material presence in the USA for over two decades," said Brad Porter, Chief Commercial Officer at HEALWELL. "We now have a unique opportunity to accelerate value for our customers by combining Orion's trusted platform with HEALWELL's next-generation AI capabilities. The robust clinical validation and data lineage features differentiates these tools in the market and ultimately reduces friction with regards to clinical adoption." HEALWELL's U.S. strategy will focus on the delivery of value-based care and population health initiatives through two critical capabilities: health data infrastructure and a suite of AI-enabled tools to be made available as a compelling offering to ACOs, CINs, HIEs, payers and health systems. As regulatory frameworks like TEFCA along with convergence of standards towards FHIR reshape the national data landscape, HEALWELL is introducing a modular, FHIR-native repository to work alongside Orion's robust HL7-based data repository. This approach enables a TEFCA-ready, standards-aligned architecture that supports longitudinal patient records, interoperability, and real-time data sharing, while providing a clear upgrade path for existing HIEs and provider networks. Complementing this foundation is HEALWELL's growing suite of AI tools which will be introduced to the market, including AI-enabled clinical search, AI-enabled clinical summarisation and AI-enabled patient identification and risk stratification. These tools are designed to integrate seamlessly into existing clinical infrastructure, helping care teams surface insights faster, reduce administrative burden, and improve clinical outcomes. "The demand for clinically validated and explainable AI is growing fast," said Dr. Alexander Dobranowski, CEO of HEALWELL. "Our ability to embed these tools into existing systems rather than replace them means we can drive impact quickly, without disrupting workflows." To deepen its U.S. market presence, HEALWELL will also focus on strategic partnerships and M&A. Dr. Dobranowski adds, "As highlighted by our track record, we will be continuing to evaluate U.S. oriented partnerships, acquisition opportunities and organic expansion to ensure capital allocation matches the ambition of HEALWELLs purpose of enabling the adoption of AI driven preventative care." Beyond providers and public health systems, HEALWELL also sees growing demand from the life sciences sector, where real-world evidence (RWE) generation, decentralized clinical trial orchestration, and identifying gaps in patient care are increasingly common. With established life sciences partnerships and a platform built for scalability, HEALWELL is well-positioned to support clinical research, clinical development, and outcomes-based engagement in the U.S. market. HEALWELL's subsidiaries Pentavere and Khure Health have an established track record with U.S. life sciences and health system organizations and are currently commercially active with 7 of the top 10 largest pharmaceutical companies globally. "We're seeing real traction and a path to significant growth," said James Lee, incoming CEO of HEALWELL. "We're making excellent progress on integration and go-to-market plans, and we're seeing significant opportunities to both expand responsibly and rationalize expenses to improve operating margins. We're at the start of the curve in proving how AI can improve patient outcomes and help healthcare systems become more targeted with their resources. It's an exciting time for the industry." HEALWELL's U.S. oriented portfolio of capabilities will include HEALWELL Data as a Service, a FHIR complaint data store and a growing suite of AI-enabled tools that support clinical search, patient clinical summarisation, patient identification and patient risk stratification. These capabilities complement Orion Health's established and scaled U.S. offerings, including Amadeus Digital Care Record, Virtuoso Digital Front Door, and Communicate Direct Secure Messaging, creating an integrated platform that will deliver both infrastructure and intelligence to the frontlines of care. Dr. Alexander DobranowskiChief Executive OfficerHEALWELL AI Inc. 1 About HEALWELL HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTCQX Market under the symbol "HWAIF". To learn more about HEALWELL, please visit Forward-Looking Statements Certain statements in this press release, constitute "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including statements about the potential for HEALWELL and Orion Health to develop new products and services, or to enhance or combine existing ones, and the anticipated impact of such products and services; and the anticipated timing, focus and implementation of Healwell's strategic expansion into the U.S. Market; and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements are often, but not always, identified by words or phrases such as "mission", "opportunity", "introducing", "is engaging", "continue to", "improve" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms . Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward-looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: HEALWELL's ability to integrate Orion Health personnel, products, services, customers and relationships; HEALWELL's and Orion Health's ability to maintain and leverage their relationships with their commercial partners; the continued adoption of the software, tools and solutions created by HEALWELL and its subsidiaries; that HEALWELL will be successful in identifying, executing and integrating new acquisitions, investments and/or partnerships, the stability of general economic and market conditions; sufficiency of working capital and access to financing; HEALWELL's ability to comply with applicable laws and regulations; HEALWELL's continued compliance with third party intellectual property rights; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; technologies working as intended or at all; trends in customer growth and the adoption of new technologies in the industry; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated March 31, 2025, which is available under HEALWELL's SEDAR+ profile at The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements. For more information: Pardeep S. SanghaInvestor Relations, HEALWELL AI 604-572-6392ir@ To view the source version of this press release, please visit Sign in to access your portfolio
National Post
28-05-2025
- Business
- National Post
WELL Health Reports HEALWELL AI and WELLSTAR Subsidiaries Are Selected for Canada Health Infoway's Vendor Innovation Program
Article content WELL Health is pleased to report that HEALWELL's wholly owned subsidiary Intrahealth, non-wholly owned subsidiary Pentavere along with WELLSTAR's subsidiary OceanMD have been selected by Canada Health Infoway as recipients for the 2025 Vendor Innovation Program. The Vendor Innovation Program is designed to accelerate the development, clinical implementation and adoption of interoperability in healthcare settings across Canada. Intrahealth, Pentavere and OceanMD are engaging in projects that accelerate the adoption of interoperability by improving data quality, enhancing care coordination, and expanding access to standardized, actionable health information for patients and clinicians across Canada. Their projects were selected not only based on technical merit, but for their demonstrated potential to deliver real, lasting impact on Canada's digital health priorities. Three out of the eight winners of the Vendor Innovation Program are from the WELL Health and HEALWELL families. This achievement highlights the group's leadership and innovation in the digital health sector, further solidifying its role in transforming healthcare in Canada. Article content Article content VANCOUVER, British Columbia & TORONTO — WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ('WELL' or the 'Company'), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that HEALWELL AI Inc. (TSX: AIDX, OTCQX: HWAIF)(' HEALWELL '), and WELLSTAR Technologies Inc. (' WELLSTAR '), subsidiaries, Intrahealth Systems Limited ('Intrahealth'), (non-wholly owned) Pentavere Research Group Inc. ('Pentavere'), and 2355581 Ontario Inc. dba OceanMD ('OceanMD'), have been selected by Canada Health Infoway (' Infoway '), as recipients of the 2025 Vendor Innovation Program (VIP), recognizing integrated, forward-looking solutions that will help advance connected care, improve patient access to their health information, and enhance care coordination across the Canadian health system. Article content Infoway's Vendor Innovation Program (VIP) is designed to accelerate the development and clinical implementation of real-world interoperability innovations that are aligned with the Shared Pan-Canadian Interoperability Roadmap. The program empowers selected vendors to develop and implement innovations that accelerate the adoption of interoperability. This year's winning projects exemplify how innovation can accelerate the adoption of interoperability by improving data quality, enhancing care coordination, and expanding access to standardized, actionable health information for patients and clinicians. Article content 'The Vendor Innovation Program is a critical component in mobilizing Canada's digital health industry,' says Abhi Kalra, Executive Vice President, Connected Care at Canada Health Infoway. 'By supporting the implementation of real-world solutions in clinical settings, we are helping to demonstrate what's possible when innovation is aligned with national priorities and focused on the needs of patients and care teams.' Article content Dr. Alexander Dobranowski, CEO of HEALWELL, said, 'Intrahealth and Pentavere's recognition through the Vendor Innovation Program demonstrates the tremendous impact HEALWELL companies are having in the digital health landscape. Both companies are at the forefront of transforming healthcare delivery with innovative solutions that enhance data-driven care coordination, streamline workflows, and empower clinicians to deliver better patient outcomes. We remain committed to improving patient care and supporting healthcare providers with actionable insights, while also focusing on addressing the needs of underserved and rural communities, where our technology can make the most meaningful difference.' Article content Amir Javidan, CEO of WELLSTAR, said, 'We are incredibly proud to see OceanMD, as part of WELLSTAR, recognized for its innovation in improving healthcare outcomes through digital technologies. This recognition is a testament to the exceptional work our team is doing in transforming patient care, and we are excited to see the impact this will have in clinical settings across Canada. In total, WELL Health and HEALWELL companies have earned significant recognition in this prestigious program, with three out of the eight winners coming from the WELL Health family. This achievement highlights our leadership and innovation in the digital health sector, further solidifying our role in transforming healthcare across Canada.' Article content Selected from more than 40 applications across the country, the 2025 VIP cohort reflects the breadth of Canada's healthcare landscape, including solutions targeting primary care, acute care, and Indigenous and rural communities. The three recipient projects from the WELL Health family are as follows: Article content Pentavere: Integrating its DARWEN™ AI system with EMRs to generate clinician-facing patient summaries, reducing chart review time and improving provider efficiency. OceanMD: Enhancing its eReferral system with open APIs and AI automation to streamline referral workflows and support real-time clinical decision-making. Intrahealth: Developing standardized FHIR-based tools to enable seamless, accurate transfer of full patient records between EMR systems across Canada. Article content These projects were selected not only for their technical merit, but for their demonstrated potential to deliver real, lasting impact on Canada's digital health priorities. These three initiatives will be deployed in live clinical environments, across Alberta, British Columbia, Ontario, New Brunswick, and Nova Scotia, providing tangible value to patients, clinicians, and health system leaders. Article content WELL HEALTH TECHNOLOGIES CORP. Article content Per: 'Hamed Shahbazi' Hamed Shahbazi Chief Executive Officer, Chairman and Director WELL Health Technologies Inc. Article content WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: Article content Canada Health Infoway (Infoway) is an independent, not-for-profit organization funded by the federal government and accountable to its Board of Directors and Members of the Corporation (Canada's 14 federal, provincial and territorial deputy ministers of health). Infoway is led by a team of seasoned professionals who are specialists in their respective fields, including health care, administration, information technology and privacy. Learn more online at Article content Certain statements in this press release, constitute 'forward-looking information' and 'forward looking statements' (collectively, 'forward looking statements') within the meaning of applicable Canadian securities laws, including the Company's, WELLSTAR's, and HEALWELL's plan to further develop and deploy technologies in clinical environments. Forward-looking statements are often, but not always, identified by words or phrases such as 'building', 'scaling', 'to become', 'opportunity', 'burgeoning', 'continue to', 'focus', 'believe', 'pursue', 'entering', 'growth', 'expect', 'intend', 'anticipate' or variations of such words and phrases or statements that certain future conditions, actions, events or results 'will', 'may', 'could', 'would', 'should', 'might' or 'can' be taken, occur or be achieved, or the negative of any of these terms. Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by the Company, HEALWELL, and WELLSTAR as of the date of such statements, are outside of their control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to: WELL's, HEALWELL's and WELLSTAR's ability to further develop the technologies identified above, and identifying customers interested in deploying such technologies in a clinical environment; the continued adoption of the software, tools and solutions created by WELL, WELLSTAR and HEALWELL; sufficiency of working capital and access to financing; WELL's, WELLSTAR's and HEALWELL's ability to comply with applicable laws and regulations; technologies working as intended or at all; trends in customer growth and the adoption of new technologies in the industry; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. Article content Known and unknown risk factors, many of which are beyond the control of WELL and HEALWELL, could cause the actual results of WELL and HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled 'Risk Factors' in WELL's most recent annual information form dated April 15, 2025, which is available under WELL's SEDAR+ profile, and HEALWELL's most recent annual information form dated March 31, 2025, which is available under HEALWELL's SEDAR+ profile. The risk factors are not intended to represent a complete list of the factors that could affect WELL and HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. WELL and HEALWELL disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements. Article content Article content Article content Contacts Article content For more information: Article content Article content Article content
Business Wire
28-05-2025
- Business
- Business Wire
WELL Health Reports HEALWELL AI and WELLSTAR Subsidiaries Are Selected for Canada Health Infoway's Vendor Innovation Program
VANCOUVER, British Columbia & TORONTO--(BUSINESS WIRE)--WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ('WELL' or the 'Company'), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that HEALWELL AI Inc. (TSX: AIDX, OTCQX: HWAIF)(' HEALWELL '), and WELLSTAR Technologies Inc. (' WELLSTAR '), subsidiaries, Intrahealth Systems Limited ("Intrahealth"), (non-wholly owned) Pentavere Research Group Inc. ("Pentavere"), and 2355581 Ontario Inc. dba OceanMD ("OceanMD"), have been selected by Canada Health Infoway (' Infoway '), as recipients of the 2025 Vendor Innovation Program (VIP), recognizing integrated, forward-looking solutions that will help advance connected care, improve patient access to their health information, and enhance care coordination across the Canadian health system. Infoway's Vendor Innovation Program (VIP) is designed to accelerate the development and clinical implementation of real-world interoperability innovations that are aligned with the Shared Pan-Canadian Interoperability Roadmap. The program empowers selected vendors to develop and implement innovations that accelerate the adoption of interoperability. This year's winning projects exemplify how innovation can accelerate the adoption of interoperability by improving data quality, enhancing care coordination, and expanding access to standardized, actionable health information for patients and clinicians. 'The Vendor Innovation Program is a critical component in mobilizing Canada's digital health industry,' says Abhi Kalra, Executive Vice President, Connected Care at Canada Health Infoway. 'By supporting the implementation of real-world solutions in clinical settings, we are helping to demonstrate what's possible when innovation is aligned with national priorities and focused on the needs of patients and care teams.' Dr. Alexander Dobranowski, CEO of HEALWELL, said, 'Intrahealth and Pentavere's recognition through the Vendor Innovation Program demonstrates the tremendous impact HEALWELL companies are having in the digital health landscape. Both companies are at the forefront of transforming healthcare delivery with innovative solutions that enhance data-driven care coordination, streamline workflows, and empower clinicians to deliver better patient outcomes. We remain committed to improving patient care and supporting healthcare providers with actionable insights, while also focusing on addressing the needs of underserved and rural communities, where our technology can make the most meaningful difference.' Amir Javidan, CEO of WELLSTAR, said, 'We are incredibly proud to see OceanMD, as part of WELLSTAR, recognized for its innovation in improving healthcare outcomes through digital technologies. This recognition is a testament to the exceptional work our team is doing in transforming patient care, and we are excited to see the impact this will have in clinical settings across Canada. In total, WELL Health and HEALWELL companies have earned significant recognition in this prestigious program, with three out of the eight winners coming from the WELL Health family. This achievement highlights our leadership and innovation in the digital health sector, further solidifying our role in transforming healthcare across Canada.' Selected from more than 40 applications across the country, the 2025 VIP cohort reflects the breadth of Canada's healthcare landscape, including solutions targeting primary care, acute care, and Indigenous and rural communities. The three recipient projects from the WELL Health family are as follows: Pentavere: Integrating its DARWEN™ AI system with EMRs to generate clinician-facing patient summaries, reducing chart review time and improving provider efficiency. OceanMD: Enhancing its eReferral system with open APIs and AI automation to streamline referral workflows and support real-time clinical decision-making. Intrahealth: Developing standardized FHIR-based tools to enable seamless, accurate transfer of full patient records between EMR systems across Canada. These projects were selected not only for their technical merit, but for their demonstrated potential to deliver real, lasting impact on Canada's digital health priorities. These three initiatives will be deployed in live clinical environments, across Alberta, British Columbia, Ontario, New Brunswick, and Nova Scotia, providing tangible value to patients, clinicians, and health system leaders. WELL HEALTH TECHNOLOGIES CORP. Per: 'Hamed Shahbazi' Hamed Shahbazi Chief Executive Officer, Chairman and Director WELL Health Technologies Inc. WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: About Canada Health Infoway Canada Health Infoway (Infoway) is an independent, not-for-profit organization funded by the federal government and accountable to its Board of Directors and Members of the Corporation (Canada's 14 federal, provincial and territorial deputy ministers of health). Infoway is led by a team of seasoned professionals who are specialists in their respective fields, including health care, administration, information technology and privacy. Learn more online at Forward Looking Statements Certain statements in this press release, constitute "forward-looking information" and "forward looking statements" (collectively, "forward looking statements") within the meaning of applicable Canadian securities laws, including the Company's, WELLSTAR's, and HEALWELL's plan to further develop and deploy technologies in clinical environments. Forward-looking statements are often, but not always, identified by words or phrases such as "building', 'scaling', 'to become', 'opportunity', 'burgeoning', 'continue to', 'focus', 'believe', 'pursue', 'entering', 'growth', 'expect', 'intend', 'anticipate' or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms. Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by the Company, HEALWELL, and WELLSTAR as of the date of such statements, are outside of their control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to: WELL's, HEALWELL's and WELLSTAR's ability to further develop the technologies identified above, and identifying customers interested in deploying such technologies in a clinical environment; the continued adoption of the software, tools and solutions created by WELL, WELLSTAR and HEALWELL; sufficiency of working capital and access to financing; WELL's, WELLSTAR's and HEALWELL's ability to comply with applicable laws and regulations; technologies working as intended or at all; trends in customer growth and the adoption of new technologies in the industry; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. Known and unknown risk factors, many of which are beyond the control of WELL and HEALWELL, could cause the actual results of WELL and HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in WELL's most recent annual information form dated April 15, 2025, which is available under WELL's SEDAR+ profile, and HEALWELL's most recent annual information form dated March 31, 2025, which is available under HEALWELL's SEDAR+ profile. The risk factors are not intended to represent a complete list of the factors that could affect WELL and HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. WELL and HEALWELL disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
